Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 8/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119561 | 0.87 | PIM1 (0.48) | CYP2D6CYP1A2KDM1AMAOACHRM2 | |
| SCHEMBL5114986 | 0.84 | ADRA2A (0.49) | CYP2D6CYP1A2KDM1AMAOACHRM2 | |
| SCHEMBL12561711 | 0.84 | FPR2 (0.57) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| SCHEMBL5998189 | 0.83 | BCHE (0.45) | CYP2D6CYP1A2HRH1BCHESMN1; SMN2 | |
| SCHEMBL12536832 | 0.82 | KDM1A (0.54) | CYP2D6CYP1A2KDM1AMAOACHRM2 | |
| SCHEMBL23954425 | 0.80 | BCHE (0.54) | KDM1AMAOACHRM2ADRA2ACHRM1 | |
| SCHEMBL11258249 | 0.80 | CYP2D6 (0.49) | CYP2D6CYP1A2KDM1AMAOACHRM2 | |
| SCHEMBL5116460 | 0.79 | L3MBTL3 (0.48) | BCHESMN1; SMN2 | |
| Acetamide SCHEMBL27709114 | 0.79 | GFER (0.43) | CYP2D6CYP1A2CHRM2CHRM1SLC6A2 | |
| SCHEMBL5504478 | 0.79 | CYP2D6 (0.41) | CYP2D6CYP1A2KDM1AMAOACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-9399032-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-20120136007-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | PINK1, PC, PCK2 | CYP2D6 2734/4885CYP1A2 3151/4885KDM1A 1783/4885 |
| US-20120136007-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | PINK1, PC, PCK2 | CYP2D6 2734/4885CYP1A2 3151/4885KDM1A 1783/4885 |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | PINK1, PC, PCK2 | CYP2D6 2734/4885CYP1A2 3151/4885KDM1A 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.